214 related articles for article (PubMed ID: 31479762)
1. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
[TBL] [Abstract][Full Text] [Related]
2. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
[TBL] [Abstract][Full Text] [Related]
4. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
5. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections.
Bhagunde P; Patel P; Lala M; Watson K; Copalu W; Xu M; Kulkarni P; Young K; Rizk ML
CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):748-758. PubMed ID: 31508899
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.
Wu J; Racine F; Wismer MK; Young K; Carr DM; Xiao JC; Katwaru R; Si Q; Harradine P; Motyl M; Bhagunde PR; Rizk ML
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507068
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
9. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
[TBL] [Abstract][Full Text] [Related]
10. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
[TBL] [Abstract][Full Text] [Related]
11. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
[TBL] [Abstract][Full Text] [Related]
12. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
13. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
[TBL] [Abstract][Full Text] [Related]
14. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
Barnes MD; Bethel CR; Alsop J; Becka SA; Rutter JD; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530851
[No Abstract] [Full Text] [Related]
16. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR; Rybak JM; Claeys KC
Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
[TBL] [Abstract][Full Text] [Related]
17.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
[TBL] [Abstract][Full Text] [Related]
18.
Asempa TE; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262769
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.
Horner C; Mushtaq S; Livermore DM;
J Antimicrob Chemother; 2019 Jul; 74(7):1940-1944. PubMed ID: 31032858
[TBL] [Abstract][Full Text] [Related]
20. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]